



Fig. 8 | **Schematic algorithm for multidisciplinary treatment of bone metastases and myeloma bone disease.** Sequential systemic treatments for the underlying cancer are dependent on tumour biology and clinical features and are accompanied by regular imaging for assessment of treatment response to guide treatment changes. Bone-targeted treatments are recommended following diagnosis of bone involvement and continued throughout the clinical course of the disease. In addition to these

treatments, symptom control incorporating pain management, treatment of skeletal-related events if and when they occur with radiotherapy and/or surgery, and specialist clinical, nursing and palliative care support are necessary to reduce the clinical impact of the underlying disease, preserve quality of life and maintain physical functioning for as long as possible. BTA, bone-targeted agent; CR, complete remission; PR, partial remission. Adapted with permission from REF<sup>3</sup>, Elsevier.